MYC基因参与了细胞增殖、代谢、衰老、凋亡和血管生成等多个生物学过程的调控。c-MYC癌基因在70%肿瘤中的高表达与肿瘤发生发展、侵袭、耐药和不良预后密切相关，使其成为肿瘤治疗的重要靶点。由于c-MYC具有无序结构域并且缺乏小分子药物结合口袋，靶向c ...

Clinicopathological Significance 基因组分析显示，8q24.1位点的c-MYC扩增与HCC晚期分期、血管浸润和不良预后密切相关。 组织微阵列技术证实，c-MYC过表达患者对索拉非尼等酪氨酸激酶抑制剂（TKIs）响应率更低。 Ribozymes as a Gene Therapy Strategy ...

机制研究发现，USP33与c-Myc直接相互作用，特异性去除其K48位泛素链，阻断蛋白酶体降解途径，延长c-Myc半衰期。 恢复实验证实，过表达c-Myc可逆转USP33敲低对糖酵解和恶性表型的抑制作用，确立了两者的上下游关系。

C-Myc的过表达与肿瘤形成高度相关，但直接靶向c-Myc目前来说仍有较大挑战。 因此发现参与 c-Myc 失调的关键因素对于开发 c-Myc 的潜在间接靶点具有 ...

c-myc nullizygous fibroblasts (KO cells) were used to compare the abilities of c-myc, N-myc and L-myc oncoproteins to accelerate growth, promote apoptosis, revert morphology, and regulate the ...

c-MYC is a well-validated oncogene with broad anti-cancer potential, as c-MYC expression is dysregulated in more than 70% of cancers and a key regulator in nearly every aspect of the oncogenic ...

Conclusions: A high c-Myc expression in naïve CC might discriminate patients with a lower TTP and a worse prognosis. Moreover, the significant c-Myc pathway upregulation, unrelated to miRNAs ...